Steven Nottley

Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903

Linda Mileshkin, Richard J. Edmondson, Rachel O’Connell et al. · Gynecologic Oncology · 2019 · 61 citations

Medicine, Gynecology, Oncology +11

A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial

Susana Banerjee, Mónica Tang, Rachel O’Connell et al. · Gynecologic Oncology · 2021 · 42 citations

Medicine, Endocrinology, Oncology +14

No-biopsy strategy for coeliac disease is applicable in adult patients: a ‘real-world’ Scottish experience

Aoisha Hoyle, Peter M. Gillett, Helen Gillett et al. · Frontline Gastroenterology · 2022 · 29 citations · Full text

Medicine, Immunology, Internal Medicine +17

Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)

Michael Friedländer, Charlotte Benson, Rachel O’Connell et al. · Gynecologic Oncology · 2021 · 15 citations · Full text

Medicine, Gynecology, Oncology +11

Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)

Richard J. Edmondson, Rachel O’Connell, Susana Banerjee et al. · Gynecologic Oncology · 2021 · 15 citations · Full text

Medicine, Oncology, Pharmacology +13